Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 1259994
                    [Title] => Oncolytics says Reolysin slowed progression of head and neck cancer in late-stage study
                    [Summary] => 
Oncolytics Biotech said Thursday that its drug Reolysin slowed the progression of head and neck cancers in a late-stage clinical trial.

                    [DatePublished] => 2013-11-23 07:00:06
                    [ColumnID] => 0
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Health And Family
                    [SectionUrl] => health-and-family
                    [URL] => http://img834.imageshack.us/img834/1294/46r7.jpg
                )

            [1] => Array
                (
                    [ArticleID] => 26899
                    [Title] => Strong quad muscles may slow knee osteoarthritis
                    [Summary] => 
            
                    [DatePublished] => 2007-11-11 00:00:00
                    [ColumnID] => 136231
                    [Focus] => 0
                    [AuthorID] => 1805110
                    [AuthorName] => Charles C. Chante MD
                    [SectionName] => Opinion
                    [SectionUrl] => opinion
                    [URL] => 
                )

            [2] => Array
                (
                    [ArticleID] => 289788
                    [Title] => Managing metabolic syndrome with ‘fenofibrates’
                    [Summary] => Fenofibrate has been shown to reduce risk of coronary events, including non-fatal heart attack and stroke, in patients with metabolic syndrome. 


A study demonstrated the benefits of fenofibrate therapy in atherogenic dyslipidemia, a common risk factor for metabolic syndrome, a constellation of risk factors which also include obesity, insulin resistance and hypertension.


Atherogenic dyslipidemia is characterized by high-triglycerides, low high-density lipoprotein (HDL) and the preponderance of small low-density lipoprotein.  


                    [DatePublished] => 2005-08-04 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

PROGRESSION

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 1259994
                    [Title] => Oncolytics says Reolysin slowed progression of head and neck cancer in late-stage study
                    [Summary] => 
Oncolytics Biotech said Thursday that its drug Reolysin slowed the progression of head and neck cancers in a late-stage clinical trial.

                    [DatePublished] => 2013-11-23 07:00:06
                    [ColumnID] => 0
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Health And Family
                    [SectionUrl] => health-and-family
                    [URL] => http://img834.imageshack.us/img834/1294/46r7.jpg
                )

            [1] => Array
                (
                    [ArticleID] => 26899
                    [Title] => Strong quad muscles may slow knee osteoarthritis
                    [Summary] => 
            
                    [DatePublished] => 2007-11-11 00:00:00
                    [ColumnID] => 136231
                    [Focus] => 0
                    [AuthorID] => 1805110
                    [AuthorName] => Charles C. Chante MD
                    [SectionName] => Opinion
                    [SectionUrl] => opinion
                    [URL] => 
                )

            [2] => Array
                (
                    [ArticleID] => 289788
                    [Title] => Managing metabolic syndrome with ‘fenofibrates’
                    [Summary] => Fenofibrate has been shown to reduce risk of coronary events, including non-fatal heart attack and stroke, in patients with metabolic syndrome. 


A study demonstrated the benefits of fenofibrate therapy in atherogenic dyslipidemia, a common risk factor for metabolic syndrome, a constellation of risk factors which also include obesity, insulin resistance and hypertension.


Atherogenic dyslipidemia is characterized by high-triglycerides, low high-density lipoprotein (HDL) and the preponderance of small low-density lipoprotein.  


                    [DatePublished] => 2005-08-04 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

abtest

Oncolytics says Reolysin slowed progression of head and neck cancer in late-stage study

November 23, 2013 - 7:00am

Oncolytics Biotech said Thursday that its drug Reolysin slowed the progression of head and neck cancers in a late-stage clinical...

Health And Family

Strong quad muscles may slow knee osteoarthritis

By YOUR DOSE OF MEDICINE | By Charles C. Chante MD | November 11, 2007 - 12:00am

Opinion

Managing metabolic syndrome with ‘fenofibrates’

August 4, 2005 - 12:00am

Fenofibrate has been shown to reduce risk of coronary events, including non-fatal heart attack and stroke, in patients with metabolic syndrome. A study demonstrated the benefits of fenofibrate therapy in atherogenic...

Science and Environment